FIRST Registry: Follow-up in Rivaroxaban Patients in the Setting of Thromboembolism

Trial Profile

FIRST Registry: Follow-up in Rivaroxaban Patients in the Setting of Thromboembolism

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 Accrual to date is 10% according to United Kingdom Clinical Research Network.
    • 13 Nov 2015 Accrual to date is 9% according to United Kingdom Clinical Research Network.
    • 07 Oct 2015 Accrual to date is 8% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top